Loading chart…

Incyte Corporation: “That one makes no sense that it’s down here. I think you got a really good one. I think you should maybe buy even more than you have. I don’t get it. This company actually makes money. It’s real good. I think the big boys are going to come to it. Nice call.”

Loading chart…

Nautilus Biotechnology: “That’s an Andreessen Horowitz-[backed] company. Look, this is one is too small for me to just point-blank say, ‘You’re absolutely right. We’ve got to love it.’ I’ve got to do more work on it. It does seem very strange because [Amazon founder Jeff] Bezos, it looks like they’re very involved . It’s an odd one. Let me do some work.”

Loading chart…

Corning: “They’re unassailable in terms of their manufacturing, but in terms of making money with that manufacturing, there are so many other better companies. I cannot recommend their stock.”

Loading chart…

Icahn Enterprises: “No. I think it’s variable, [which] is the problem. I don’t know what’s in Icahn Enterprises. He doesn’t tell us. I wish I knew, so therefore it’s too much of a black box for me to recommend.”

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com

You May Also Like

Rocket builder Firefly takes on high-speed Space Force mission for crucial next launch

The Alpha rocket for the Space Force’s Victus Nox mission stands on…

Russell Westbrook traded to Los Angeles Lakers in blockbuster deal with Washington Wizards

Russell Westbrook #4 of the Washington Wizards reacts prior to playing against…

Rodent infestation leads to recalls at more than 400 Family Dollar stores

A woman walks by a Family Dollar store on December 11, 2018…

Rising cases and deaths test Singapore’s pivot to treat Covid as endemic

SINGAPORE — Rising Covid-19 infections and deaths are testing Singapore’s long-term strategy…